Crinetics Pharmaceuticals, Inc. SEC Filing (Sep 11, 2026)
Crinetics Pharmaceuticals, Inc. filed a Form 15 with the SEC to terminate its registration under the Securities Exchange Act of 1934. The company cited Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) as the basis for this termination, which is effective as of September 11, 2026. The filing indicates that the company has one holder of record. Charles Wagner, President of Crinetics Pharmaceuticals, Inc., signed the document.
How this was made
The 30-second read
Why it matters
The filing signals a shift away from public market compliance, which may affect investor perception and share liquidity.
Market read
Primary disclosure with modest trading relevance; mainly of interest to current shareholders and OTC traders.
What to watch
Potential hidden cash reserves or pending partnership that are not disclosed due to reduced reporting.
Background
Crinetics Pharmaceuticals filed a Form 15 to terminate its registration, a routine corporate filing for companies ceasing public reporting.
Ticker impact
SEC Form 15 filing terminating Crinetics' registration under Section 12(g), indicating delisting or suspension of reporting obligations.
Possible short-term price pressure due to reduced investor confidence and lower liquidity.
Delisting filings are primary disclosures but typically have limited material impact for small-cap biotech unless accompanied by a merger or liquidation plan.
Market effects
May affect other small-cap biotech stocks as investors reassess reporting risks.
U.S. OTC market sees a minor liquidity reduction.
Limited to niche biotech investors.
Counterpoint
The delisting could make CRNX an attractive target for a reverse merger or private acquisition.
Key entities
- companyCrinetics Pharmaceuticals, Inc.
Biotech firm filing to terminate its SEC registration.
